Clinical Trial Update: Efficacy Study of GS010 for the Treatment of Vision Loss up to 6 Months From Onset in LHON Due to the ND4 Mutation [Phase 3]

View source ↗

Summary

GenSight Biologics completed a Phase 3 efficacy study of GS010 for vision loss due to Leber hereditary optic neuropathy (ND4 mutation). Results were posted in J…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leber Hereditary Optic Neuropathy

Drugs mentioned

• GS010 (lenadogene nolparvovec)

Snippet

Sponsor: GenSight Biologics | Conditions: Optic, Atrophy, Hereditary, Leber | Phase 3 | Status: COMPLETED | Results posted: 2020-01-28